Nasdaq · CIK 0001404281
ELDN Eledon Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jan 13, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Eledon Pharmaceuticals, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 27 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | Allan Kirk director | AGrant or award Stock Option (right to buy)derivative | +30,870 | $0.00 | $0 | 30,870 | Jan 13, 2025 |
| Jan 10, 2025 | June Lee director | AGrant or award Stock Option (right to buy)derivative | +30,870 | $0.00 | $0 | 30,870 | Jan 13, 2025 |
| Jan 10, 2025 | Jan Hillson director | AGrant or award Stock Option (right to buy)derivative | +30,870 | $0.00 | $0 | 30,870 | Jan 13, 2025 |
| Jan 10, 2025 | Steven Perrin President | AGrant or award Stock Option (right to buy)derivative | +243,000 | $0.00 | $0 | 243,000 | Jan 13, 2025 |
| Jan 10, 2025 | Paul Sean Little Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 13, 2025 |
| Jan 10, 2025 | John S. McBride director | AGrant or award Stock Option (right to buy)derivative | +30,870 | $0.00 | $0 | 30,870 | Jan 13, 2025 |
| Jan 10, 2025 | Bryan E. Smith General Counsel, Corporate Sec | AGrant or award Stock Option (right to buy)derivative | +150,500 | $0.00 | $0 | 150,500 | Jan 13, 2025 |
| Jan 10, 2025 | David-Alexandre C Gros Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jan 13, 2025 |
| Jan 10, 2025 | Keith Katkin director | AGrant or award Stock Option (right to buy)derivative | +77,175 | $0.00 | $0 | 77,175 | Jan 13, 2025 |
| Jan 10, 2035 | James A. Robinson Jr. director | AGrant or award Stock Option (right to buy)derivative | +30,870 | $0.00 | $0 | 30,870 | Jan 13, 2025 |
| Jan 10, 2025 | Keith Katkin director | AGrant or award Restricted Stock Unitsderivative | +8,575 | $0.00 | $0 | 8,575 | Jan 13, 2025 |
| Jan 10, 2025 | Jan Hillson director | AGrant or award Restricted Stock Unitsderivative | +3,430 | $0.00 | $0 | 3,430 | Jan 13, 2025 |
| Jan 10, 2025 | John S. McBride director | AGrant or award Restricted Stock Unitsderivative | +3,430 | $0.00 | $0 | 3,430 | Jan 13, 2025 |
| Jan 10, 2025 | David-Alexandre C Gros Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +66,500 | $0.00 | $0 | 66,500 | Jan 13, 2025 |
| Jan 10, 2025 | Bryan E. Smith General Counsel, Corporate Sec | AGrant or award Restricted Stock Unitsderivative | +64,500 | $0.00 | $0 | 64,500 | Jan 13, 2025 |
| Jan 10, 2025 | James A. Robinson Jr. director | AGrant or award Restricted Stock Unitsderivative | +3,430 | $0.00 | $0 | 3,430 | Jan 13, 2025 |
| Jan 10, 2025 | Paul Sean Little Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +75,000 | $0.00 | $0 | 75,000 | Jan 13, 2025 |
| Jan 10, 2025 | Steven Perrin President | AGrant or award Restricted Stock Unitsderivative | +27,000 | $0.00 | $0 | 27,000 | Jan 13, 2025 |
| Jan 10, 2025 | June Lee director | AGrant or award Restricted Stock Unitsderivative | +3,430 | $0.00 | $0 | 3,430 | Jan 13, 2025 |
| Jan 10, 2025 | Allan Kirk director | AGrant or award Restricted Stock Unitsderivative | +3,430 | $0.00 | $0 | 3,430 | Jan 13, 2025 |
| Nov 21, 2024 | David-Alexandre C Gros Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +1,015,743 | $0.00 | $0 | 1,015,743 | Nov 22, 2024 |
| Nov 21, 2024 | Steven Perrin President | AGrant or award Stock Option (right to buy)derivative | +840,438 | $0.00 | $0 | 840,438 | Nov 22, 2024 |
| Nov 21, 2024 | Paul Sean Little Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +525,032 | $0.00 | $0 | 525,032 | Nov 22, 2024 |
| Nov 21, 2024 | Bryan E. Smith General Counsel, Corporate Sec | AGrant or award Stock Option (right to buy)derivative | +474,350 | $0.00 | $0 | 474,350 | Nov 22, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il owner | POpen-market purchase Pre-funded Warrants to Purchase Common Stockderivative | +2,213,816 | $3.65 | $8.1M | 7,415,596 | Oct 31, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il owner | POpen-market purchase Pre-funded Warrants to Purchase Common Stockderivative | +2,100,244 | $3.65 | $7.7M | 6,235,545 | Oct 31, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il owner | POpen-market purchase Pre-funded Warrants to Purchase Common Stockderivative | +440,489 | $3.65 | $1.6M | 838,507 | Oct 31, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- David-Alexandre C GrosChief Executive Officer
- Jan Hillsondirector
- Keith Katkindirector
- Allan Kirkdirector
- June Leedirector
- Paul Sean LittleChief Financial Officer
- John S. McBridedirector
- Steven PerrinPresident
- James A. Robinson Jr.director
- Bryan E. SmithGeneral Counsel, Corporate Sec
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.